Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

First in Human Study of TORL-3-600 in Participants With Advanced Cancer

Study ID: NCT05948826
Start Date: 2023-09-29
End Date: 2026-09-15
Study Type

Interventional

Study Phase

Phase1

No. of Participants

70

Intervention / Treatment

TORL-3-600

Sponsor

TORL Biotherapeutics, LLC

Source: clinicaltrials.gov

Share:
Add to list

International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

Study ID: NCT05363657
Start Date: 2022-01-10
End Date: 2028-12-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

10000

Intervention / Treatment

Partial Nephrectomy (PN)

Radical Nephrectomy (RN)

Ablation therapy (AT)

Active Surveillance (AS)

Sponsor

Careggi Hospital-University

Source: clinicaltrials.gov

Share:
Add to list

Effects of Simvastatin on Uterine Leiomyoma Size

Study ID: NCT03400826
Start Date: 2018-08-20
End Date: 2025-07-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

60

Intervention / Treatment

Simvastatin 40mg

Placebo 40 mg

Sponsor

Johns Hopkins University

Source: clinicaltrials.gov

Share:
Add to list

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Study ID: NCT06789757
Start Date: 2025-02-25
End Date: 2027-01-27
Study Type

Interventional

Study Phase

Phase2

No. of Participants

19

Intervention / Treatment

Memantine Hydrochloride

Infatuating

Atezolizumab

Sponsor

Inova Health Care Services

Source: clinicaltrials.gov

Share:
Add to list

NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Study ID: NCT06919666
Start Date: 2025-06
End Date: 2031-02
Study Type

Interventional

Study Phase

Phase2

No. of Participants

29

Intervention / Treatment

19

Sponsor

University of Colorado, Denver

Source: clinicaltrials.gov

Share:
Add to list

AOH1996 for the Treatment of Refractory Solid Tumors

Study ID: NCT05227326
Start Date: 2022-08-12
End Date: 2026-01-29
Study Type

Interventional

Study Phase

Phase1

No. of Participants

92

Intervention / Treatment

PCNA Inhibitor AOH1996

Sponsor

City of Hope Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Study ID: NCT06790966
Start Date: 2025-05-30
End Date: 2029-02
Study Type

Interventional

Study Phase

Phase3

No. of Participants

351

Intervention / Treatment

Combination Treatment of PDS0101 and Pembrolizumab

Pembrolizumab Monotherapy

Sponsor

PDS Biotechnology Corp.

Source: clinicaltrials.gov

Share:
Add to list

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Study ID: NCT05493566
Start Date: 2022-11-01
End Date: 2027-01-07
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

15

Intervention / Treatment

Aldesleukin

Pembrolizumab

Sponsor

Emory University

Source: clinicaltrials.gov

Share:
Add to list

Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

Study ID: NCT00579566
Start Date: 2002-06
End Date: 2025-06
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

3000

Intervention / Treatment

Specimen protocol

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Study ID: NCT05090566
Start Date: 2021-10-27
End Date: 2027-10-23
Study Type

Interventional

Study Phase

Phase2

No. of Participants

120

Intervention / Treatment

Alranattamb + Nirogke

Elranatamab + lenalidomide + dexamethasone

Sponsor

Pfizer

Source: clinicaltrials.gov

Share:
Add to list